Diana Kouiavskaia1, Zhaochun Chen2, Eugenia Dragunsky1, Olga Mirochnitchenko1, Robert Purcell2, Konstantin Chumakov3. 1. Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA. 2. National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. 3. Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 52, Room 1126, Silver Spring, MD 20993-0002, USA. Electronic address: konstantin.chumakov@fda.hhs.gov.
Abstract
BACKGROUND: Development of anti-poliovirus therapies to complement vaccination is an urgent priority. A number of antiviral drugs are in development. Recently we have developed human monoclonal antibodies that could be used for treatment of chronically infected individuals and emergency response to potential reappearance of polioviruses after eradication. OBJECTIVE: The aim of this study was to characterize neutralizing activity of anti-poliovirus monoclonal antibody A12 against wild type, vaccine-derived, and drug-resistant poliovirus strains, evaluate in vivo pre- and post-exposure protective properties of the antibody against polioviruses of serotypes 1 and 2, and to determine whether it interferes with response to immunization with poliovirus vaccine. STUDY DESIGN: Immunogenicity studies were performed in CD1 mice. Poliovirus neutralizing titers were determined in poliovirus microneutralization assay. Poliovirus immunization-challenge experiments were performed in poliovirus-susceptible TgPVR21 mice. RESULTS: We show that monoclonal antibody A12 effectively neutralizes in vitro a broad range of type 1 and type 2 wild and vaccine-derived polioviruses, provides effective pre- and post-exposure protection of TgPVR21 mice from challenge with a lethal dose of poliovirus. Treatment of animals with the antibody concurrent with IPV immunization does not prevent immune response to the vaccine. CONCLUSIONS: Anti-poliovirus antibody A12 effectively neutralizes a range of wild and VDPV strains and protectstransgenic mice susceptible to poliovirus against lethal challenge upon pre- and post-exposure administration. This suggests that the antibodies could be used in combination with drugs and/or vaccine to improve their efficacy and prevent emergence of resistant variants, and provides a justification for initiating their clinical evaluation. Published by Elsevier B.V.
BACKGROUND: Development of anti-poliovirus therapies to complement vaccination is an urgent priority. A number of antiviral drugs are in development. Recently we have developed human monoclonal antibodies that could be used for treatment of chronically infected individuals and emergency response to potential reappearance of polioviruses after eradication. OBJECTIVE: The aim of this study was to characterize neutralizing activity of anti-poliovirus monoclonal antibody A12 against wild type, vaccine-derived, and drug-resistant poliovirus strains, evaluate in vivo pre- and post-exposure protective properties of the antibody against polioviruses of serotypes 1 and 2, and to determine whether it interferes with response to immunization with poliovirus vaccine. STUDY DESIGN: Immunogenicity studies were performed in CD1mice. Poliovirus neutralizing titers were determined in poliovirus microneutralization assay. Poliovirus immunization-challenge experiments were performed in poliovirus-susceptible TgPVR21 mice. RESULTS: We show that monoclonal antibody A12 effectively neutralizes in vitro a broad range of type 1 and type 2 wild and vaccine-derived polioviruses, provides effective pre- and post-exposure protection of TgPVR21 mice from challenge with a lethal dose of poliovirus. Treatment of animals with the antibody concurrent with IPV immunization does not prevent immune response to the vaccine. CONCLUSIONS: Anti-poliovirus antibody A12 effectively neutralizes a range of wild and VDPV strains and protectstransgenic mice susceptible to poliovirus against lethal challenge upon pre- and post-exposure administration. This suggests that the antibodies could be used in combination with drugs and/or vaccine to improve their efficacy and prevent emergence of resistant variants, and provides a justification for initiating their clinical evaluation. Published by Elsevier B.V.
Authors: Olen M Kew; Roland W Sutter; Esther M de Gourville; Walter R Dowdle; Mark A Pallansch Journal: Annu Rev Microbiol Date: 2005 Impact factor: 15.500
Authors: Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Geoffrey L Ray; Kayhan Garmestani; Mark Williams; Martin W Brechbiel Journal: Cancer Biother Radiopharm Date: 2008-10 Impact factor: 3.099
Authors: Diana V Kouiavskaia; Eugenia M Dragunsky; Hong-Mei Liu; M Steven Oberste; Marc S Collett; Konstantin M Chumakov Journal: Antivir Ther Date: 2011
Authors: Rajiva de Silva; Sunethra Gunasena; Damayanthi Ratnayake; G D Wickremesinghe; C D Kumarasiri; B A W Pushpakumara; Jagadish Deshpande; Anna Lea Kahn; Roland W Sutter Journal: Vaccine Date: 2012-10-22 Impact factor: 3.641
Authors: Rong Deng; Kelly M Loyet; Samantha Lien; Suhasini Iyer; Laura E DeForge; Frank-Peter Theil; Henry B Lowman; Paul J Fielder; Saileta Prabhu Journal: Drug Metab Dispos Date: 2010-01-13 Impact factor: 3.922